The specific reasons and relevant regulations for fezolinetant being banned in China

Fezolinetant (Fezolinetant) is an innovative non-hormonal drug used to treat hot flashes in menopausal women. Although the drug has been approved for marketing in the United States and Europe, it has not been officially approved by the National Medical Products Administration (NMPA) in China and therefore cannot be sold in the domestic market. This means that patients and doctors currently cannot obtain the drug through formal channels.

China has a very strict approval process for new drugs, and drugs must undergo complete clinical trial data review and registration approval before they can be marketed. Although Fezonatant has conducted multiple phases of clinical trials internationally, the clinical research in China has not yet completed all approval procedures, and the relevant marketing applications are still in progress. Therefore, the drug is temporarily in the status of "unapproved and prohibited from sale".

In addition, the related patent rights of fezonatant are strictly protected by R&D companies, and a number of patents including crystal forms, salt forms, etc. have been applied for in China, limiting the possibility of other companies developing generic drugs. This kind of patent protection has affected the research and development progress of domestic generic drugs to a certain extent, and has also made the entry of fezonatant into the Chinese market more slowly.

To sum up, the main reason why Fezolnetam has been "banned" in China is because the approval process of the State Food and Drug Administration has not been completed, and patent protection has restricted the research and development of generic drugs. In the future, only after meeting regulatory requirements and obtaining formal approval, can Fezonatan legally enter the Chinese market and provide new treatment options for more menopausal women.

Reference materials:https://www.drugs.com/